Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer ; volume:9 ; number:1 ; day:11 ; month:8 ; year:2023 ; pages:1-9 ; date:12.2023
npj Breast cancer ; 9, Heft 1 (11.8.2023), 1-9, 12.2023

Creator: Khorrami, Mohammadhadi
Viswanathan, Vidya Sakar
Reddy, Priyanka
Braman, Nathaniel
Kunte, Siddharth
Gupta, Amit
Abraham, Jame
Montero, Alberto J.
Madabhushi, Anant

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41523-023-00574-7

URN: urn:nbn:de:101:1-2024020512365704756859

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:35 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Khorrami, Mohammadhadi
Viswanathan, Vidya Sakar
Reddy, Priyanka
Braman, Nathaniel
Kunte, Siddharth
Gupta, Amit
Abraham, Jame
Montero, Alberto J.
Madabhushi, Anant
SpringerLink (Online service)

Other Objects (12)

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population

Regulation of CDK4

Radiomic Analysis of CT Predicts Tumor Response in Human Lung Cancer with Radiotherapy

Hochschulschrift

Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer

Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma

Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer

Gene expression predicts dormant metastatic breast cancer cell phenotype

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population

Regulation of CDK4

Radiomic Analysis of CT Predicts Tumor Response in Human Lung Cancer with Radiotherapy

Hochschulschrift

Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer

Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma

Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer

Gene expression predicts dormant metastatic breast cancer cell phenotype

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population

Regulation of CDK4

Radiomic Analysis of CT Predicts Tumor Response in Human Lung Cancer with Radiotherapy

Hochschulschrift

Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer

Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma

Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer

Gene expression predicts dormant metastatic breast cancer cell phenotype

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population

Regulation of CDK4

Radiomic Analysis of CT Predicts Tumor Response in Human Lung Cancer with Radiotherapy

Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer

Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma

Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer

Gene expression predicts dormant metastatic breast cancer cell phenotype

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population

Regulation of CDK4

Radiomic Analysis of CT Predicts Tumor Response in Human Lung Cancer with Radiotherapy

Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer

Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma

Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer

Gene expression predicts dormant metastatic breast cancer cell phenotype

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population

Regulation of CDK4

Radiomic Analysis of CT Predicts Tumor Response in Human Lung Cancer with Radiotherapy

Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer

Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma

Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer

Gene expression predicts dormant metastatic breast cancer cell phenotype

Related objects

Reset password